CClinicalTrials.gg
RecruitingNCT06432465Updated Jun 29, 2026

tDCS to Decrease Opioid Relapse (UH3)

An interventional study of active tDCS and sham tDCS in Opioid Use Disorder, sponsored by Butler Hospital. Recruiting at 1 site in United States. Open to participants aged 21 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-06-29.

Sponsored by Butler Hospital · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
21 Years to 60 Years
Sex
All
01

Study summary

Investigators will measure behavioral and brain responses following transcranial direct current stimulation (tDCS) to the dorsolateral prefrontal cortex (DLPFC) (anode on right DLPFC, cathode on the left DLPFC) delivered during cognitive control network (CCN) priming. In Phase I, the EEG provided validation of expected changes in these networks following tDCS stimulation of the DLPFC. In this current phase (II), the investigators will perform a larger randomized clinical trial (RCT) (active vs. sham control) to address long-term neurobehavioral outcomes, including opioid relapse, craving, and sustained EEG changes.

Read the detailed description

Investigators will perform an RCT in 100 opioid dependent participants who recently initiated buprenorphine or methadone. Participants will be randomized to receive five sessions of tDCS+CCN priming stimulation vs. sham tDCS+CCN priming. Participants will be assessed three times using electroencephalographic (EEG), once prior to tDCS+CCN priming, right after the completion of 5 sessions of tDCS+CCN priming (one week later), and again 10 weeks later.

This phase will address long-term (3- and 6-month) neurobehavioral outcomes, including opioid relapse, craving, and sustained EEG changes during a paradigm that challenges networks associated with craving (CR) and cognitive control (CCN). During the 24 weeks of buprenorphine or methadone maintenance treatment, the investigators will examine our primary clinical outcome, relapse (opioid use on >4 days per month and having an opioid positive urine screen), as well as days of opioid use.

02

Conditions studied

  • Opioid Use Disorder

Keywords

  • opioid craving
  • buprenorphine
  • methadone
  • EEG
  • transcranial direct current stimulation
03

Who can participate

Ages eligible
21 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. current opioid dependence
  2. between 21-60 years of age
  3. recent initiation of buprenorphine or methadone (≤90 days)
  4. enrolled in Butler Hospital's Alcohol and Drug Inpatient Unit, Alcohol and Drug Partial Hospital Treatment Program, Intensive Outpatient Services, or Outpatient Services at Butler Hospital OR receive opioid-treatment services in the community.

Exclusion criteria

Exclusion Criteria:

  1. current diagnosis of organic brain disorder (e.g., Parkinson's disease, Huntington's disease, multiple sclerosis, intracranial mass/infection, hydrocephalus)
  2. bipolar, schizophrenia, schizoaffective, or schizophreniform disorder, or current psychosis associated with any disorder
  3. current suicidality
  4. evidence of significant neurocognitive dysfunction
  5. conditions associated with heightened tDCS risks, e.g., seizure disorder, nonremovable intracranial metal objects (other than dental fillings and dental implants), skin disease or active lesions on the scalp, migraine/other headache disorder with significant active symptoms, traumatic brain injury or skull fracture within the past year, any implanted medical devices or device components that can interact with electromagnetic fields or are controlled by physiological signals
  6. probation/parole requirements or an upcoming move that might interfere with protocol participation
  7. planning to terminate buprenorphine or methadone in less than 3 months
  8. current pregnancy or plan to become pregnant in the next month.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Active comparator
    active tDCS

    Each participant will undergo 5 consecutive (i.e., business days) sessions of active tDCS delivered to the DLPFC. During each session, participants are engaging in tasks that activate the cognitive control network.

    Device: active tDCS

  • Sham comparator
    sham tDCS

    Each participant will undergo 5 consecutive (i.e., business days) sessions of sham tDCS delivered to the DLPFC. During each session, participants are engaging in tasks that activate the cognitive control network.

    Device: sham tDCS

Interventions

  • Deviceactive tDCS

    The anode will be placed over the right DLPFC (F4 on the EEG 10-20 system) and the cathode over the left DLPFC65 (F3) using 25cm2 sponges at an intensity of 2mA. Stimulation will be delivered for 20 minutes via two saline-soaked surface sponge electrodes and a battery-driven, constant current stimulator (NeuroConn DC Stimulator Plus).

  • Devicesham tDCS

    Same device and procedures as active tDCS with the exception that the device includes a study mode, in which subject-specific codes are entered to deliver active or sham stimulation, keeping the administrator blinded. Sham stimulation will use a method in which stimulation will be ramped up and back down over a 30-second period at the beginning and end of sham tDCS.

05

What researchers measure

Primary outcomes

  1. Opioid Craving

    Modified Penn Alcohol Craving (0 = no craving to 30 = extreme craving)

    Time frame: 2 weeks

Secondary outcomes

  1. EEG theta activity

    theta event rate during working memory task

    Time frame: 2 weeks

  2. opioid relapse

    Timeline Follow back

    Time frame: 24 weeks

06

Study locations

1 of 1 sites recruiting
  • Butler Hospital
    Providence, Rhode Island 02906, United States
    • Ana M Abrantes, Ph.D. · Contact · ana_abrantes@brown.edu · 4014556440
    • Ana M. Abrantes, Ph.D. · Principal investigator
    • Michael Stein, M.D. · Principal investigator
    Recruiting
07

References and documents

Individual participant data

Plan to share: Yes — Data will be shared online at ICPSR.

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT06432465
Lead sponsor
Butler Hospital
Collaborators
National Institute on Drug Abuse (NIDA)
Responsible party
Sponsor
First posted
May 29, 2024
Start date
Apr 17, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jun 29, 2026

Study contacts

Ana M Abrantes, Ph.D.
Contact
ana_abrantes@brown.edu
4014556440
Julie A Desaulniers, M.S.
Contact
jdesaulniers@butler.org
4014556219
Abrantes Abrantes, Ph.D.
principal investigator · Butler Hospital
Michael Stein, M.D.
principal investigator · Boston University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion